Last reviewed · How we verify
Mumps vaccine
The mumps vaccine stimulates the immune system to produce antibodies and cellular immunity against the mumps virus, preventing infection and disease.
The mumps vaccine stimulates the immune system to produce antibodies and cellular immunity against the mumps virus, preventing infection and disease. Used for Prevention of mumps infection in children and adults.
At a glance
| Generic name | Mumps vaccine |
|---|---|
| Sponsor | Sinovac (Dalian) Vaccine Technology Co., Ltd. |
| Drug class | Live attenuated vaccine |
| Target | Mumps virus surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live attenuated (weakened) mumps virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize wild-type mumps virus upon exposure, preventing symptomatic infection and its complications.
Approved indications
- Prevention of mumps infection in children and adults
Common side effects
- Fever
- Local injection site reactions (pain, erythema, swelling)
- Parotitis (mumps-like symptoms)
- Rash
- Mild allergic reactions
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (PHASE3)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mumps vaccine CI brief — competitive landscape report
- Mumps vaccine updates RSS · CI watch RSS
- Sinovac (Dalian) Vaccine Technology Co., Ltd. portfolio CI